Literature DB >> 32666759

Large-cell Neuroendocrine Carcinoma of the Endometrium in Myomatous Uterus.

Spasimir T Shopov1, Benyamin L Anavi2, Dobrin K Krastev3.   

Abstract

Large-cell neuroendocrine carcinoma of the endometrium is an insufficiently researched aggressive tumor with a short survival regard-less of the treatment type.We present here the 38th consecutive case of literature reported cases of large cell neuroendocrine carcinoma of the endometrium (posi-tive for synaptophysin, CD56, chromogranin A, p53, and Vimentin) found in the myomatous uterus of a 76-year-old woman.We also describe in the study the morphological algorithm for differentiation of malignant blastomas with small (under 10 %) neuro-endocrinal component.Accumulated clinical and morphological evidence raises the question whether the large-cell and the small-cell neuroendocrine carcino-mas are just different variations according to their histology and topical occurrence (uterine body/cervix) or they are just independent forms with their respective clinical signs, morphology, treatment, and prognosis. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Entities:  

Keywords:  immunohistochemistry; large-cell neuroendocrine carcinoma of the endometrium; myomatous uterus

Mesh:

Substances:

Year:  2020        PMID: 32666759     DOI: 10.3897/folmed.62.e49815

Source DB:  PubMed          Journal:  Folia Med (Plovdiv)        ISSN: 0204-8043


  2 in total

1.  Primary Neuroendocrine Tumors of the Endometrium: Management and Outcomes.

Authors:  Jingjing Zhang; Li Pang
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

2.  Clinical characteristic and prognostic factors in high-grade endometrial neuroendocrine carcinoma.

Authors:  Zhifang Zhang; Jing Wang; Xiaomei Wu; Yuan Liu; Xiaowei Xi
Journal:  J Obstet Gynaecol Res       Date:  2022-07-01       Impact factor: 1.697

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.